Table 1 Baseline, all patients
All (43,636) | AMC (30,721) | AMX (12,915) | p-value | |
|---|---|---|---|---|
Age, median* (IQR) | 69 (62–77) | 70 (62–77) | 69 (61–76) | < 0.0001 |
Age* | < 0.0001 | |||
≤ 62 (Q1) | 10,502 | 7156 (23%) | 3346 (26%) | |
63–69 (Q2) | 9820 | 6884 (22%) | 2936 (23%) | |
70–77 (Q3) | 12,127 | 8662 (28%) | 3465 (27%) | |
≥ 78 (Q4) | 11,187 | 8019 (26%) | 3168 (25%) | |
Gender female | 23,010 | 16,171 (53%) | 6839 (53%) | 0.55 |
FEV1* | < 0.0001 | |||
FEV1 ≥ 80% | 2289 | 1438 (5%) | 851 (7%) | |
50% ≤ FEV1 ≤ 80% | 15,778 | 10,775 (38%) | 5003 (43%) | |
30% ≤ FEV1 ≤ 50% | 14,729 | 10,659 (38%) | 4070 (35%) | |
FEV1 ≤ 30% | 7149 | 5416 (19%) | 1733 (15%) | |
Exacerbations within the past year* | 0 | 24,499 (80%) | 11,543 (89%) | < 0.0001 |
1 | 3880 (13%) | 902 (7%) | ||
≥ 2 | 2342 (8%) | 470 (4%) | ||
BMI, median* (IQR) | 25.0 (21.0–29.0) | 24.9 (21.0–29.0) | 25.0 (22.0–29.0) | < 0.0001 |
BMI* (kg/m2) | < 0.0001 | |||
10.0–18.4 | 3991 | 2994 (11%) | 997 (8%) | |
18.5–24.9 | 15,763 | 11,254 (40%) | 4509 (38%) | |
25.0–29.9 | 11,823 | 8252 (29%) | 3571 (30%) | |
≥ 30 | 8625 | 5946 (21%) | 2679 (23%) | |
Smoking | 0.64 | |||
Current smokers | 14,049 | 9916 (35%) | 4133 (35%) | |
Ex-/Non-smokers | 25,886 | 18,329 (65%) | 7557 (65%) | |
Prednisolone treatment for exacerbation* | No prednisolone | 22,290 (73%) | 11,692 (91%) | < 0.0001 |
Short course treatment | 5900 (19%) | 979 (8%) | ||
Long course treatment | 2531 (8%) | 244 (2%) | ||
Comorbidities | ||||
AFLI | 3824 | 2682 (9%) | 1142 (9%) | 0.71 |
Heart failure | 3399 | 2422 (8%) | 977 (8%) | 0.26 |
Myocardial infarction | 2700 | 1905 (6%) | 795 (6%) | 0.88 |
Hypertension* | 5800 | 4001 (13%) | 1799 (14%) | 0.0113 |
Diabetes mellitus* | 2811 | 1925 (6%) | 886 (7%) | 0.0223 |
Peripheral vascular disease | 3843 | 2684 (9%) | 1159 (9%) | 0.43 |
Cerebrovascular disease | 3366 | 2331 (8%) | 1035 (8%) | 0.13 |
Renal failure* | 989 | 661 (2%) | 328 (3%) | 0.0136 |
Depression | 719 | 514 (2%) | 205 (2%) | 0.54 |